Status:
COMPLETED
Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis
Lead Sponsor:
University Health Network, Toronto
Conditions:
Myasthenia Gravis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is a double-blind, placebo-controlled, randomized clinical trial to determine whether IVIG is effective in improving motor scores in patients with myasthenia gravis and worsening weakness.
Detailed Description
Patients aged 18 years or older with a diagnosis of myasthenia gravis (MG) and worsening weakness were enrolled in the study after providing informed consent. Fifty-two patients were recruited to the ...
Eligibility Criteria
Inclusion
- age \> or equal to 18 years old with a confirmed diagnosis of myasthenia gravis and worsening weakness
Exclusion
- age \<18; severe myasthenia gravis requiring intensive care admission; change in immunosuppresive medication in previous 3 months; patients with severe bulbar weakness at risk for aspiration and respiratory failure; patients with other serious underlying medical conditions (renal failure, congestive heart failure); unwilling to provide informed consent.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2005
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00306033
Start Date
March 1 2004
End Date
May 1 2005
Last Update
April 3 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network
Toronto, Ontario, Canada, M5G 2N2